Chad J. Kolean
Known title: Chief Financial OfficerCIK: 0001616753
Chad J. Kolean's purchase track record
Chad J. Kolean has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/2/2025 | CLRB | $25K | +22.0% | -37.6% | +9.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CLRB | ▲ Buy | Open Market | 5,000 | $25K | 7/2/2025 | View on chart |
| CLRB | ▲ Buy | Grant | 42,554 | $0 | 12/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cellectar to Present Iopofosine Data at Waldenström Workshop
Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.
Cellectar to Present Iopofosine Data at Waldenström Workshop. Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.